Improved Long-Term Clinical Outcomes And Safety Profile Of Sunitinib Dosing Schedule With 4/2 Switched To 2/1 In Patients With Metastatic Renal Cell Carcinoma

Purpose: This study aimed to identify the survival benefit and safety of alternative dosage schedules for sunitinib in metastatic renal cell carcinoma. Materials and Methods: Clinicopathologic and survival data of patients treated with sunitinib as first-line therapy were retrospectively reviewed. P...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xingming, Sun, Guangxi, Zhao, Jinge, Shu, Kunpeng, Zhao, Peng, Liu, Jiandong, Yang, Yaojing, Tang, Qidun, Chen, Junru, Shen, Pengfei, Wang, Jia, Zeng, Hao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6160671/
https://www.ncbi.nlm.nih.gov/pubmed/30271490
http://dx.doi.org/10.7150/jca.25693

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6160671/
https://www.ncbi.nlm.nih.gov/pubmed/30271490
http://dx.doi.org/10.7150/jca.25693

Ejemplares similares